Abstract: The present invention relates to an oral tablet composition for pharmaceutical use, comprising (1) a particle comprising an amorphous structure and a submicron domain and (2) a pharmaceutically acceptable carrier, wherein the composition is optionally coated.

Abstract: A topical anti-aging skin care formulation comprising an effective amount of a benzoquinone, such as CoQ10, plus a synergistic pair of stabilizers and a synergistic pair of whiteners. The stabilizers are octyl salicylate and octyl methoxycinnamate. The whiteners are titanium dioxide and zinc oxide. When proper amounts of these ingredients are used in an aqueous based emulsion formulation, the product will be initially white, and will remain white for an extended period of time.

Abstract: A cosmetic in an emulsified state, in which a titanium dioxide microparticle coated with hydrous silicic acid and/or a hydrous silicate compound, a higher alcohol, an oily component other than the higher alcohol, and a polysaccharide are contained, and the polysaccharide containing at least one of fucose, glucose, glucuronic acid and rhamnose as a constituent monosaccharide, and having fucose and/or rhamnose in a side chain is contained in an amount of 0.01% by weight to 1% by weight relative to the total amount of the cosmetic. And a cosmetic containing the higher alcohol, the oily component and the polysaccharide in an emulsified state, in which the higher alcohol is composed of two or more kinds of higher alcohols having different molecular weights, and is contained in the cosmetic in an amount of 1% by weight to 20% by weight relative to the total amount of the cosmetic.

Abstract: There is provided a surface-active material that comprises fibers which have been modified so as to impart surface-active properties onto said fibres and giving it a contact angle between 60° and 120°, wherein the fibres have an aspect ratio of more than 10 to 1,000. The surface-active material can be used for foam and emulsion formation and stabilization, coatings, encapsulation and drug delivery. It can for example be used in the following industries: foods, home and personal care, oilfield, agriculture, textile, construction, emulsion polymerization, leather, plastic, pulp, paper and pharma.

Abstract: The present invention relates to the use of compounds which enhance the transcription of endothelial nitric oxide synthase (eNOS) for treating stem and progenitor cells in the cell therapy of patients with ischemic heart diseases such as coronary heart disease or ischemic cardiomyopathy. Treatment of such cells which are isolated from bone marrow, for example, with an eNOS transcription enhancer prior to their administration improves their functional activity and ameliorates neovascularization of the heart and cardiac regeneration.

Abstract: The present invention aims at providing an adhesive preparation wherein a drug is sufficiently dissolved in an adhesive layer and is not easily separated from the adhesive layer even during preservation of the adhesive preparation. The present invention provides an adhesive preparation having an adhesive layer on at least one surface of a support, wherein the adhesive layer comprises a first synthetic rubber having a viscosity average molecular weight of 1,600,000-6,500,000, a drug, an organic liquid component and a tackifier. The present invention further provides the aforementioned adhesive preparation, wherein the organic liquid component is contained in the adhesive layer in a proportion of 20 wt % or above relative to the total weight of the adhesive layer.

Abstract: The present invention provides a method for preparing a medical device, preferably a contact lens, having an antimicrobial metal-containing LbL coating on a medical device, wherein the antimicrobial metal-containing LbL coating comprises at least one layer of a negatively charged polyionic material having —COOAg groups and/or silver nanoparticles formed by reducing Ag+ ions associated with the —COO? groups of the negatively charged polyionic material. In addition, the present invention provides a medical device prepared according to a method of the invention.

Abstract: A contact lens (4) comprises a solid component capable of imparting shape and structure to said lens, and a liquid component, at least partially contained in the solid component, capable of favoring the compatibility between said lens and the eye of a user of said lens, wherein the liquid component comprises a solution capable of being used as a lachrymal substitute.

Abstract: The present invention is directed to a method of treating cancer, particularly canine hemangiosarcoma. The method includes the continuous and regular administration of a formulation including a histone deacetylase inhibitor as part of the standard canine diet. The preferred histone deacetylase inhibitor is SAHA. The formulation is administered following splenectomy to prevent tumor recurrence.

Abstract: Compositions, methods for forming compositions, and methods for using compositions for reducing tadpole shrimp populations in temporary pools using the hormone methyl farnesoate. Compositions can include a dry base having a bulk ingredient, a viscous additive having an oily compound, a saline solution, and preparation having an effective amount of phospholipid-encapsulated methyl farnesoate. The composition can be formed by combining the dry base and the viscous additive into a first mixture and adding all or a portion of the saline solution to form a crumbly consistency. Then, the methyl farnesoate preparation can be added. The composition may then be formed into a plurality of particles having shapes and sizes for consumption by the tadpole shrimp. In use, the particles may be dispensed prior to, or immediately after, the temporary pools are flooded with water. The particles may be formed such that they can withstand exposure to water for between about 4 to about 14 days.

Abstract: The invention relates to the use of amphiphilic self-assembling proteins for formulating poorly water-soluble effect substances.

Abstract: Provided is a toothpaste composition providing a pleasant cooling sensation and has excellent storage stability. The toothpaste composition contains from 30 to 60 wt % of erythritol having an average particle size of 200 ?m or less as Component (A), from 15 to 30 wt % of water as Component (B), and from 0.6 to 3 wt % of a binder as (C1).

Abstract: The invention relates to the use of 5-acetyl-2,5-dimethyl-2-hydroxy-tetrahydrofuran-3-one (diacetyl dimer of formula (I)) in the form of one of its stereoisomers or in the form of a mixture consisting of or containing two, three or four of its stereoisomers (i) for imparting, intensifying and/or modifying a creamy and/or fatty sensation in the mouth, (ii) for imparting, intensifying and/or modifying a sweet, buttery, cream-like and/or creamy flavor; and/or (iii) as an aromatic and/or flavoring substance.

Abstract: Therapeutic skin cleansing and multifunctional coating compositions containing hydrogen peroxide and an organosilane quaternary compound in aqueous formulations are used to treat skin disorders including wounds, abrasions, ulcers, burns, infections, irritations, microbes, soil, water, psoriasis, acne vulgaris, blemishes, age spots, sclerosis, other physical or chemical injuries, and other skin deficiencies.

Abstract: The present invention discloses certain derivatives of artemisinin and the active principles contained in Artemisia annua extracts with amino acids, peptides, and amino sugars and salts thereof (formula I).

Abstract: Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.

Abstract: The invention relates to a multistage process for the continuous preparation of organic, distillable isocyanates, preferably diisocyanates, particularly preferably aliphatic or cycloaliphatic diisocyanates, by reaction of the corresponding organic amines with urea and alcohols to liberate ammonia and form low molecular weight monomeric urethanes and thermal dissociation of the latter, in which by-products formed are at least partly utilized.

Abstract: A method for producing theanine including reacting a glutamic acid alkyl ester represented by general Formula (1): where R1 represents an alkyl group, with a ketone represented by general Formula (2): where R2 represents a hydrogen atom, R3 represents a lower alkanoyl group or a benzoyl group, and R2 and R3 may form a cycloalkanone ring in combination with the vicinal carbon atom, in the presence of t-butylamine, a secondary amine or a tertiary amine, reacting the resultant compound represented by general Formula (3): where R1, R2 and R3 are the same as defined above, with ethylamine, and then being subjected to heating in the presence of the ethylamine or reaction with a fatty acid.

Abstract: The compound of formula (I) is a water-stable, long acting ?2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like.

Abstract: Compounds having the general structure: which are useful for the treatment of a variety of diseases and conditions, such as bone disorders.